The role of Lyn kinase in the development of imatinib resistance in chronic myelogenous leukemia
Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly proven...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2011-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Imatinib mesylate, a small-molecule inhibitor of BCRABL tyrosine kinase activity, has emerged as the well-recognized standard of treatment for chronic myelogenous leukemia (CML). Indeed, both its efficacy, tolerability, as well as cost-effectiveness have been clearly proven... |
|---|---|
| Item Description: | 10.4081/oncol.2008.67 1970-5557 1970-5565 |